CG Oncology, Inc. Files Amendment to Registration Statement

TL;DR

<b>CG Oncology, Inc. has filed an S-1/A amendment, signaling progress in its public offering registration.</b>

AI Summary

CG Oncology, Inc. (CGON) filed a Amended IPO Registration (S-1/A) with the SEC on January 18, 2024. CG Oncology, Inc. filed an S-1/A amendment on January 18, 2024. The company is incorporated in Delaware with its principal executive offices in Irvine, CA. The filing is related to a registration statement under the Securities Act of 1933. CG Oncology, Inc. operates in the Biological Products sector. The filing indicates the company is a non-accelerated filer, smaller reporting company, and emerging growth company.

Why It Matters

For investors and stakeholders tracking CG Oncology, Inc., this filing contains several important signals. This amendment is a procedural step in the company's journey towards becoming a publicly traded entity, indicating ongoing efforts to meet regulatory requirements for an IPO. The classification as a non-accelerated filer, smaller reporting company, and emerging growth company provides insights into the company's current size and financial reporting status.

Risk Assessment

Risk Level: low — CG Oncology, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural document for companies pursuing an IPO and does not contain new material financial or operational information that would significantly alter risk assessment.

Analyst Insight

Monitor future filings for updates on the IPO status, including pricing and effective dates.

Key Numbers

• 2024-01-18 — Filing Date (Date of S-1/A filing)
• 333-276350 — SEC File Number (SEC registration file number)
• 2836 — SIC Code (Standard Industrial Classification code for Biological Products)
• 37-1611499 — IRS Number (IRS Employer Identification No.)

Key Players & Entities

• CG Oncology, Inc. (company) — Registrant name
• January 18, 2024 (date) — Filing date
• S-1/A (filing) — Form type
• Delaware (jurisdiction) — State of incorporation
• Irvine, CA (location) — Principal executive offices
• Securities Act of 1933 (regulation) — Act under which registration is filed
• Arthur Kuan (person) — Chairman and Chief Executive Officer
• Latham & Watkins LLP (company) — Legal counsel

Forward-Looking Statements

• CG Oncology, Inc. will complete its Initial Public Offering (IPO) (CG Oncology, Inc.) — medium confidence, target: Q1 2024
• The company's stock will begin trading on a major exchange (CG Oncology, Inc.) — medium confidence, target: Q1 2024

FAQ

Industry Context

CG Oncology operates in the biotechnology sector, specifically focusing on biological products for therapeutic use.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed information on the company's business and offering.
2. Track subsequent amendments and the SEC's declaration of effectiveness for the registration statement.
3. Analyze the company's business strategy and market position as disclosed in the filing.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating ongoing regulatory processes rather than a new initial filing.

Key Financial Figures

• $16.00 — l public offering price will be between $16.00 and $18.00 per share. We have applied t
• $18.00 — fering price will be between $16.00 and $18.00 per share. We have applied to list our
• $9.9 billion — t has been forecast to be approximately $9.9 billion by 2028, according to Evaluate Pharma.

Filing Documents

• d551455ds1a.htm (S-1/A) — 2262KB
• d551455dex11.htm (EX-1.1) — 187KB
• d551455dex31.htm (EX-3.1) — 148KB
• d551455dex33.htm (EX-3.3) — 37KB
• d551455dex41.htm (EX-4.1) — 17KB
• d551455dex42.htm (EX-4.2) — 263KB
• d551455dex51.htm (EX-5.1) — 11KB
• d551455dex103.htm (EX-10.3) — 229KB
• d551455dex104.htm (EX-10.4) — 100KB
• d551455dex105.htm (EX-10.5) — 17KB
• d551455dex1018.htm (EX-10.18) — 107KB
• d551455dex231.htm (EX-23.1) — 2KB
• d551455dexfilingfees.htm (EX-FILING FEES) — 15KB
• g551455g0117130719391.jpg (GRAPHIC) — 2KB
• g551455g0117130719748.jpg (GRAPHIC) — 2KB
• g551455g03p01.jpg (GRAPHIC) — 55KB
• g551455g08o97.jpg (GRAPHIC) — 140KB
• g551455g12m13.jpg (GRAPHIC) — 144KB
• g551455g13p01.jpg (GRAPHIC) — 120KB
• g551455g15m15.jpg (GRAPHIC) — 265KB
• g551455g18g18.jpg (GRAPHIC) — 412KB
• g551455g19a20.jpg (GRAPHIC) — 162KB
• g551455g22a22.jpg (GRAPHIC) — 34KB
• g551455g23a23.jpg (GRAPHIC) — 109KB
• g551455g24a25.jpg (GRAPHIC) — 124KB
• g551455g59q43.jpg (GRAPHIC) — 176KB
• g551455g78c79.jpg (GRAPHIC) — 63KB
• g551455g88j37.jpg (GRAPHIC) — 135KB
• g551455g89m10.jpg (GRAPHIC) — 113KB
• 0001193125-24-009621.txt (&nbsp;) — 6233KB

Risk Factors

Risk Factors 14 Special Note Regarding Forward-Looking Statements 75 Market and Industry Data 76

Use of Proceeds

Use of Proceeds 77 Dividend Policy 79 Capitalization 80

Managements Discussion and Analysis of Financial

Managements Discussion and Analysis of Financial Condition and Results of Operations 85

Business

Business 101 Management 134 Page Executive and Director Compensation 142 Certain Relationships and Related Person Transactions 161 Principal Stockholders 166

Description of Capital Stock

Description of Capital Stock 168 Shares Eligible For Future Sale 174 Material United States Federal Income Tax Consequences to Non-U.S. Holders 177

Underwriting

Underwriting 181 Legal Matters 191 Experts 191 Where You Can Find More Information 191 Index to Financial Statements F-1 Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus, or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should carefully read this entire prospectus, including the information in the sections title

View Full Filing

View this S-1/A filing on SEC EDGAR